Kyntra Bio (KYNB) Assets Average (2015 - 2026)
Kyntra Bio (KYNB) posted Assets Average of $114.6 million for Q1 2026, down 10.67% sequentially from $128.3 million in Q4 2025, and down 39.64% YoY from $189.9 million in Q1 2025.
Kyntra Bio (KYNB) Assets Average (2015 - 2026) Analysis & Trends
Kyntra Bio has reported Assets Average for 12 years, with the latest figure at $114.6 million in Q1 2026.
- Quarterly Assets Average fell 39.64% year-over-year to $114.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.6 million (down 39.64% YoY) and the FY2025 annual result came in at $167.1 million, down 47.63% from the prior year.
- Assets Average fell to $114.6 million in Q1 2026 per KYNB's latest filing, from $128.3 million in the prior quarter.
- Over five years, Assets Average peaked at $759.9 million in Q1 2022 and troughed at $114.6 million in Q1 2026.
- A 5-year average of $398.2 million and a median of $394.7 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average declined 5.85% in 2022, then tumbled 51.9% in 2025.
- Over 5 years, Assets Average stood at $609.5 million in 2022, then decreased by 27.48% to $442.0 million in 2023, then sank by 45.82% to $239.5 million in 2024, then sank by 46.42% to $128.3 million in 2025, then slipped by 10.67% to $114.6 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $114.6 million, $128.3 million, and $157.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Kyntra Bio | 29.83 Mn | 29.83 Mn | 1.47 Mn | 105.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 105.35 Mn |
| Mar 31, 2026 | 114.61 Mn |
| Dec 31, 2025 | 128.30 Mn |
| Sep 30, 2025 | 157.53 Mn |
| Jun 30, 2025 | 171.63 Mn |
| Mar 31, 2025 | 189.87 Mn |
| Dec 31, 2024 | 239.47 Mn |
| Sep 30, 2024 | 278.81 Mn |
| Jun 30, 2024 | 329.54 Mn |
| Mar 31, 2024 | 394.70 Mn |
| Dec 31, 2023 | 441.98 Mn |
| Sep 30, 2023 | 487.78 Mn |
| Jun 30, 2023 | 526.84 Mn |
| Mar 31, 2023 | 574.32 Mn |
| Dec 31, 2022 | 609.46 Mn |
| Sep 30, 2022 | 647.81 Mn |
| Jun 30, 2022 | 716.36 Mn |
| Mar 31, 2022 | 759.88 Mn |
| Dec 31, 2021 | 812.17 Mn |
| Sep 30, 2021 | 829.57 Mn |